You are here

Closed

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.

Displaying 17111 - 17120 of 18915 results
  1. 078: Transthoracic Cardiac Access Ports and Closure Devices

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Summary Implanting large appliances, such as mitral valve replacement, currently requires cardiac surgery and cardiopulmonary bypass. Minithoracotomy access remains high risk. NHLBI has shown early feasibility of direct transthoracic large-port access to the beating heart, and effective closure using nitinol appliances in animal models. The objective of this contract solicitation is to support the ...

    SBIRPhase IDepartment of Health and Human Services
  2. 079: Bioabsorbable Stents for Pediatric Pulmonary Artery Stenosis and Aortic Coarctation

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Summary Mechanical stents to relieve obstructive cardiovascular lesions could have great utility in pediatric cardiology, but are unsuitable for small children. Commercially available stents limit vessel growth and require future surgical removal. Absorbable stents might revolutionize the treatment of congenital heart disease in children. Small children require small delivery systems for devices t ...

    SBIRPhase IDepartment of Health and Human Services
  3. 080: Fluorescent Nanodiamonds for In Vitro and In Vivo Biological Imaging

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Summary There is a need to develop a biocompatible fluorescent label that never photobleaches or blinks, and that is brighter than commonly used dyes. Fluorescent nanodiamonds (FNDs) are 10 to 100 nm sized biocompatible particles with indefinite photo-stability that make them superior imaging probes for a wide range of applications. Whereas organic dyes and quantum dots are neither biocompatible n ...

    SBIRPhase IDepartment of Health and Human Services
  4. 021: Aerosolized Delivery of Anti-Tubercular Drugs

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Background Many currently existing drugs for the treatment of TB, especially MDR TB are moderately potent, show restrictions with absorption or oral bioavailability, and have toxicity profiles that make patient management difficult. Aerosolized delivery offers the potential to bypass these barriers to drug efficacy by achieving high drug concentrations in the infected pulmonary tissue with lower s ...

    SBIRPhase IDepartment of Health and Human Services
  5. 022: Development of Long-Acting Formulations of HIV Anti-Retrovirals

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Background Effective treatment of HIV-infected individuals requires strict adherence to a multi-component regimen of antiretroviral agents that currently must be taken daily on a life-long basis. Non-compliance with recommended dosing regimens is a significant factor contributing to the incomplete suppression of HIV and to the development of drug resistance. The development of long-acting formulat ...

    SBIRPhase IDepartment of Health and Human Services
  6. 023: Improved Formulations for Approved First and Second line anti-Tuberculosis (TB) Drugs

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Background There is an urgent need to develop alternative formulations of approved first and second line anti-TB drugs for pediatric use and also to simplify administration. There are few child-friendly formulations of pediatric first and second-line anti-TB medications available to practitioners in the US and globally. It is standard practice to cut or crush un-scored adult tablets and administer ...

    SBIRPhase IDepartment of Health and Human Services
  7. 024: Integrated Multiplex Medical Diagnostics Platforms for Infectious Diseases

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Background NIAID supports integrated multiplex medical diagnostics platforms capable of simultaneously identifying multiple pathogens in clinical specimens (swabs, sputum, blood, serum, cerebrospinal fluid, urine, stool, etc.). Platforms that provide diagnostic information on potential early, non-specific symptoms and determine pathogen drug sensitivities are of high priority. Project Goal The fi ...

    SBIRPhase IDepartment of Health and Human Services
  8. 023: Neural Interfaces: Improving Functional Outcomes

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Summary The long term goal of neural interfaces for medical rehabilitation purposes is to replace lost functionality for people with physical disabilities. While great strides have been made in the neuroprosthetics field, the state of the art falls far short of complete restoration of function. For example, there is no consensus on the best modality for extracting signals from the central nervous ...

    SBIRPhase IDepartment of Health and Human Services
  9. 147: A Mobile Application to Help Patients Take their Pill Medications as Prescribed: Improving Medication Adherence

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    It is strongly suggested that proposals adhere to the above budget amounts and project periods. Proposals with budgets exceeding the above amounts and project periods may not be funded. Drugs don’t work in patients who don’t take them. — C. Everett Koop, M.D, former U.S. Surgeon General Medication adherence is described as the extent to which patients take medications as prescribed by their ...

    SBIRPhase IDepartment of Health and Human Services
  10. 148: Products for at-home Deactivation of Psychoactive Prescription Medicines

    Release Date: 08-15-2012Open Date: 08-15-2012Due Date: 12-03-2012Close Date: 12-03-2012

    Objective: This topic addresses the need to fund research and development activities to promote the commercial development and testing of an inexpensive prescription medicine disposal system that would provide a simple means for patients (prescription drug “end-users” defined by the Drug Enforcement Administration) or members of their household to safely render prescription drugs unusable and ...

    SBIRPhase IDepartment of Health and Human Services
US Flag An Official Website of the United States Government